Australia’s Little Green Pharma Ltd (ASX: LGP) has added to its popular LGP Classic product range with release of the first Australian made whole plant CBD cannabis oil product, LGP Classic CBD 50.
LGP Classic CBD 50 is a whole plant extract cannabidiol (CBD) oil containing 50mg/mL CBD and no tetrahydrocannabinol (THC) and complements LGP’s existing product range, which comprises:
- LGP Classic 20:5, a higher THC ratio product;
- LGP Classic 10:10, a balanced THC and CBD ratio product; and
- LGP Classic 1:20, a higher CBD ratio product.
Managing Director, Fleta Solomon, said LGP’s existing range of three LGP Classic products are already listed on the Australian Register of Therapeutic Goods (ARTG) for export, and the company is currently seeking approval for the LGP Classic CBD 50 product on the ARTG.
The launch of the LGP Classic CBD 50 product is another major milestone for the company, and we are excited to add it to our suite of Australian-made GMP manufactured products for supply to healthcare practitioners and their patients globally,” Ms Solomon said.
“LGP is now able to meet healthcare practitioners’ needs for a higher CBD ratio product.
“This is in addition to LGP’s ‘Classic’ product suite of cannabinoid medicines, all of which are locally made and GMP manufactured.
“LGP has been supplying patients with medical grade cannabis oils since the launch of our first medicines in August 2018.
We are committed to making the highest quality cannabinoid medicines accessible and available to all patients.”
LGP Classic CBD 50 is classified as a Schedule 4 medicine, which simplifies the prescription pathway for healthcare practitioners in Australia, as it does not require State Health approval in addition to TGA approval.
Recent data indicates that approximately 23% of all medicinal cannabis products prescribed in Australia were CBD products, with cannabis oil oral solutions the most commonly prescribed medicinal cannabis product.
Ms Solomon said that since launching its first medicinal cannabis product in August 2018, LGP and its exclusive GMP-licensed manufacturing partner have accrued more than one and a half years of experience and expertise in developing, cultivating, manufacturing and selling medicinal cannabis products in Australia, as well as developing relationships with medical practitioners nationally.
“This experience and GMP capability strongly position LGP to continue developing international pathways for the supply of its medicinal cannabis products into global markets,” she said.
